Phase 2b trial in 558 adults with type 2 diabetes and CKD: tozorakimab blocked IL-33 signalling but did not significantly reduce UACR vs placebo over 24 weeks (-23% to -25% vs -22%; per-protocol n=465). No safety concerns.
RCTn = 558
Hofherr et al. Inhibition of IL-33 in Diabetic Kidney Disease: A Randomized, Placebo-Controlled Phase 2b Trial